STRATEC SE

Regulatory Filings • Jun 28, 2006

News Details

Ad-hoc | 28 June 2006 08:57

STRATEC concludes major agreement for design of next generation instrumentation

Ad hoc announcement transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. —————————————————————————— STRATEC concludes major agreement for design of next generation instrumentation Birkenfeld, June 28, 2006 STRATEC Biomedical Systems AG (SIN: 728900 / ISIN: DE0007289001) today announced the conclusion of an exclusive agreement to develop fully automated instrumentation for one of the key players acting worldwide successfully in the field of molecular diagnostics. STRATEC’s partner will make an up-front payment followed by additional payments based on STRATEC’s achievement of product development milestones. Initial payments under the agreement will total less than USD 2 million, about 20 – 25% of the overall development payments to STRATEC. The analyzer system is conceived as our partner’s next generation molecular diagnostics platform intended to automate their current and future portfolio of proprietary DNA and RNA testing systems for Screening, Monitoring and Diagnosis. The parties have agreed to begin to negotiate the modalities for the manufacture and supply of the analyzer system in an early phase of the development project, which is scheduled to span a period of about three years. ————————————————————————— Information and Explaination of the Issuer to this News: Hermann Leistner, STRATEC’s founder and Chief Executive Officer, commented, ‘This agreement is another major milestone in STRATEC’s company history as it allows us to draw on our expertise in the development of instrumentation for molecular diagnostic applications – the fastest growing segment of the diagnostics market.’ About STRATEC STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (SIN: 728900 / ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, in the Gate-M trading segment of the Stuttgart Stock Exchange and on other exchanges. The STRATEC Group comprises the listed holding company ‘STRATEC Biomedical Systems AG’, as well as the subsidiaries ‘STRATEC NewGen’, ‘Robion’ and ‘Sanguin’. Further information can be obtained from: STRATEC Biomedical Systems AG André Loy, Investor Relations Gewerbestrasse 37, 75217 Birkenfeld Germany Tel: +49 7082 7916-190 Fax: +49 7082 7916-999 E-Mail: ir@stratec-biomedical.de (c)DGAP 28.06.2006 ————————————————————————— Language: English Issuer: STRATEC Biomedical Systems AG Gewerbestraße 37 75217 Birkenfeld Deutschland Phone: +49 (0)7082 7916 0 Fax: +49 (0)7082 7916 999 E-mail: info@stratec-biomedical.de WWW: www.stratec-biomedical.de ISIN: DE0007289001 WKN: 728900 Indices: Listed: Geregelter Markt in Frankfurt (Prime Standard), Stuttgart; Freiverkehr in Berlin-Bremen, München, Düsseldorf End of News DGAP News-Service —————————————————————————